Brief: Jazz Pharmaceuticals Q3 Adjusted EPS USD 8.13 Vs. IBES Estimate USD 5.97
05/11/2025 21:05
Nov 05 (Reuters) - Jazz Pharmaceuticals Q3 revenue USD 1,126.107 million vs. IBES estimate USD 1,109 million. Q3 net income USD 251.412 million Q3 adjusted net income USD 500.653 million vs. IBES estimate USD 369.8 million Q3 EPS USD 4.08
Recent news on Jazz Pharmaceuticals
See all newsBrief: Jazz Pharmaceuticals Enters Amendment No. 4 To Credit Agreement On Sept 23, 2026
U.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Jazz Pharma dips after upsized $1.1 bln convertible offering
Brief: Jazz Pharmaceuticals Announces Private Offering Of $1.0 Billion Of Exchangeable Senior Notes Due 2032